Section 5: Patient Safety and Quality Assurance

5PSQ-068​

INCIDENCE OF POST-ARTESUNATE-INDUCED HAMOLYSIS AFTER SEVERE MALARIA

5PSQ-067​

ARE POLY (ADP-RIBOSE) POLYMERASE INHIBITORS WELL TOLERATED BY OUR PATIENTS? A SAFETY STUDY IN REAL-WORD PRACTICE

5PSQ-066

PATIENT OUTCOMES AFTER THE IMPLEMENTATION OF A HUMANISED ENHANCED RECOVERY AFTER KNEE JOINT REPLACEMENT SURGERY PROGRAMME

5PSQ-065

INMUNOTHERAPY: RECOGNISING AND TREATING ADVERSE EFFECTS

5PSQ-063

PERSISTENCE OF TYROSINE KINASE INHIBITORS IN ADVANCED RENAL CELL CARCINOMA

5PSQ-062

REAL CLINICAL PRACTICE RESULTS OF INTERLEUKIN23 BLOCKERS IN REFRACTORY PSORIASIS

5PSQ-060​

LONG-TERM EFFECTIVENESS OF OMALIZUMAB FOR CHRONIC IDIOPATHIC URTICARIA IN CLINICAL PRACTICE

5PSQ-055

LONG-TERM EFFECTIVENESS OF ADALIMUMAB IN SECONDLINE OF BIOLOGICAL THERAPY IN ULCERATIVE COLITIS AND INFLUENCE OF THE FIRST-LINE TREATMENT

5PSQ-054

ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH ANTIANGIOGENIC DRUGS: A RARE BUT SERIOUS COMPLICATION

5PSQ-053​

INFLUENCE OF AUGMENTED RENAL CLEARANCE IN THE LOWER INCIDENCE OF LINEZOLID-RELATED HAEMATOLOGICAL TOXICITY

5PSQ-051

COST-EFFECTIVENESS OF A PRESURGICAL PHARMACEUTICAL CARE CONSULTATION

5PSQ-048

ANALYSIS OF THE UNIT DOSE SYSTEM OF MEDICATION DISTRIBUTION IN MENTAL HEALTH PHARMACY

5PSQ-046

IMPACT OF THE COVID-19 PANDEMIC ON A NOTIFICATION AND LEARNING SYSTEM FOR PATIENT SAFETY IN A PSYCHIATRIC HOSPITAL

5PSQ-045

ANALYSIS OF ANTIPSYCHOTIC POLYTHERAPY IN A PSYCHIATRIC HOSPITAL

5PSQ-044

CONCILIATION AND PHARMACEUTICAL CARE ON DISCHARGE IN THE PSYCHIATRIC PATIENT

Pages